N.N. Blokhin Russian Cancer Research Center / Российский онкологический научный центр им. Н. Н. Блохина
Research facility
Location:
Moscow / Moskau,
Russian Federation (RU)
ISNI: -
ROR: https://ror.org/00ab9fg88
Show on Map:
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021)
Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al.
Journal article
Challenging the prognostic impact of the new WHO and TNM classifications with special emphasis on HPV status in penile carcinoma (2019)
Hölters S, Khalmurzaev O, Pryalukhin A, Loertzer P, Janssen M, Heinzelbecker J, Ueberdiek S, et al.
Journal article
Quality assurance guidelines for interstitial hyperthermia (2019)
Trefna HD, Schmidt M, Van Rhoon GC, Kok HP, Gordeyev SS, Lamprecht U, Marder D, et al.
Journal article
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine (2014)
Grob JJ, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, et al.
Journal article
Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma (2014)
Pisareva E, Gutkina N, Kovalenko S, Kuehnapfel S, Hartmann A, Heinzerling L, Schneider-Stock R, et al.
Journal article